# Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

> **NCT03303950** · PHASE2 · TERMINATED · sponsor: **University of Utah** · enrollment: 6 (actual)

## Conditions studied

- Anemia
- ASXL1 Gene Mutation
- EZH2 Gene Mutation
- IDH1 Gene Mutation
- IDH2 Gene Mutation
- Plasma Cell Myeloma
- Primary Myelofibrosis
- Recurrent Plasma Cell Myeloma
- Secondary Myelofibrosis
- Thrombocytopenia

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **PROCEDURE:** Hematopoietic Cell Transplantation
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03303950
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-30
- **Primary completion:** 2019-05-14
- **Final completion:** 2020-02-19
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2022-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03303950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03303950, "Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03303950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*